T1	Intervention 257 355	three different treatment modalities for symptomatic metastatic hormone-resistant prostatic cancer
T2	Intervention 409 567	treated with estramustine phosphate, another with Epirubicin plus Medroxyprogesterone acetate (MPA), while the third arm consisted of Epirubicin plus placebo.
